Skip to main content

Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.

Publication ,  Journal Article
Corey, GR; Arhin, FF; Wikler, MA; Sahm, DF; Kreiswirth, BN; Mediavilla, JR; Good, S; Fiset, C; Jiang, H; Moeck, G; Kabler, H; Green, S ...
Published in: Int J Antimicrob Agents
November 2016

Oritavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). The phase 3 studies SOLO I and SOLO II demonstrated comparable efficacy and safety of a single dose of oritavancin compared with 7-10 days of twice-daily vancomycin in adults with acute bacterial skin and skin-structure infections (ABSSSIs). The present analysis assessed clinical responses by pathogen at 48-72 h and at study days 14-24 in SOLO patients within the pooled data set. Of the 1959 patients in the pooled SOLO studies, 1067 had at least one baseline Gram-positive pathogen and 405 had MRSA. Clinical response rates were similar for oritavancin- and vancomycin-treated patients by pathogen, including Staphylococcus aureus with or without the Panton-Valentine leukocidin (pvl) gene and from different clonal complexes, and were similar for pathogens within each treatment group. Oritavancin exhibited potent in vitro activity against all baseline pathogens, with MIC90 values (minimum inhibitory concentration required to inhibit 90% of the isolates) of 0.12 µg/mL for Staphylococcus  aureus, 0.25 µg/mL for Streptococcus pyogenes and 0.06 µg/mL for Enterococcus faecalis. Whereas both oritavancin and vancomycin achieved similarly high rates of clinical response by pathogen, including methicillin-susceptible and -resistant Staphylococcus aureus, oritavancin provides a single-dose alternative to 7-10 days of twice-daily vancomycin to treat ABSSSIs.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Antimicrob Agents

DOI

EISSN

1872-7913

Publication Date

November 2016

Volume

48

Issue

5

Start / End Page

528 / 534

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Skin Diseases, Bacterial
  • Middle Aged
  • Microbiology
  • Microbial Sensitivity Tests
  • Male
  • Lipoglycopeptides
  • Humans
  • Gram-Positive Bacterial Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Corey, G. R., Arhin, F. F., Wikler, M. A., Sahm, D. F., Kreiswirth, B. N., Mediavilla, J. R., … SOLO I, SOLO II Investigators, . (2016). Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents, 48(5), 528–534. https://doi.org/10.1016/j.ijantimicag.2016.07.019
Corey, G Ralph, Francis F. Arhin, Matthew A. Wikler, Daniel F. Sahm, Barry N. Kreiswirth, José R. Mediavilla, Samantha Good, et al. “Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus.Int J Antimicrob Agents 48, no. 5 (November 2016): 528–34. https://doi.org/10.1016/j.ijantimicag.2016.07.019.
Corey GR, Arhin FF, Wikler MA, Sahm DF, Kreiswirth BN, Mediavilla JR, Good S, Fiset C, Jiang H, Moeck G, Kabler H, Green S, O’Riordan W, SOLO I, SOLO II Investigators. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 2016 Nov;48(5):528–534.

Published In

Int J Antimicrob Agents

DOI

EISSN

1872-7913

Publication Date

November 2016

Volume

48

Issue

5

Start / End Page

528 / 534

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Skin Diseases, Bacterial
  • Middle Aged
  • Microbiology
  • Microbial Sensitivity Tests
  • Male
  • Lipoglycopeptides
  • Humans
  • Gram-Positive Bacterial Infections